A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme [glioblastoma].

Trial Profile

A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme [glioblastoma].

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Temozolomide (Primary) ; Sorafenib
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 May 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 02 May 2011 Status changed from active, no longer recruiting to completed. as reported by ClinicalTrials.gov.
    • 18 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top